UNC2025 - Names and Identifiers
Name | UNC2025
|
Synonyms | CS-2109 UNC2025 UNC2025 UNC-2025 UNC 2025 UNC 2025. BEMPEDOIC ACID, ESP-55016 (1r,4r)-4-(2-(Butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimi (1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol Cyclohexanol, 4-[2-(butylamino)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-,trans- (1R,4R)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol UNC-2025
|
CAS | 1429881-91-3
|
UNC2025 - Physico-chemical Properties
Molecular Formula | C28H40N6O
|
Molar Mass | 476.66 |
Storage Condition | -20℃ |
In vitro study | In 697 B- ALL cells, UNC-2025 potently inhibited Mer phosphorylation with an IC50 of 2.7 nM. In A549 NSCLC and Molm-14 AML cell lines, UNC-2025 significantly inhibited Mer8 and Flt3 dependent colony formation. In the H2228 and H1299 cell lines, UNC-2025 inhibited the downstream of MERTK oncogenic signals, such as basal and stimulated pAKT and pERK1/2. Of the four NSCLC cell lines, UNC-2025 also induced apoptotic cell death and reduced colony formation. |
In vivo study | In mice bearing 697 acute leukemic tumors, UNC-2025 (3 mg/kg, p.o.) showed good solubility and DMPK performance and elicited potent target inhibition. In mice bearing H2228 or A549 tumors, UNC-2025 (50 mg/kg, p.o.) inhibited tumor growth. |
UNC2025 - Preparation solution concentration reference
| 1mg | 5mg | 10mg |
---|
1 mM | 2.098 ml | 10.49 ml | 20.979 ml |
5 mM | 0.42 ml | 2.098 ml | 4.196 ml |
10 mM | 0.21 ml | 1.049 ml | 2.098 ml |
5 mM | 0.042 ml | 0.21 ml | 0.42 ml |
Last Update:2024-01-02 23:10:35
UNC2025 - Introduction
UNC2025 is a chemical compound that is a specific molecular inhibitor that can inhibit the activity of certain enzymes.
UNC2025 works by inhibiting specific protein kinases. It was found to inhibit the activity of BRD4 protein kinase, thereby regulating gene expression. BRD4 plays an important role in cell cycle regulation, transcriptional control and inflammatory response. UNC2025 is also being studied for the treatment of certain cancers, such as leukemia.
The preparation of UNC2025 includes chemical synthesis and purification steps. The specific preparation method may involve more complex organic synthesis reactions and chromatographic techniques.
When using UNC2025, you need to pay attention to some safety information. Since UNC2025 is a protein kinase inhibitor, it may cause side effects in vivo. In addition, UNC2025 is a chemical and should be stored and handled properly to avoid inhalation, ingestion or contact with skin and eyes. When using UNC2025, you should follow the relevant laboratory safety operation procedures and operate according to the safety information provided in the product manual. If you encounter any discomfort or unexpected situation, you should immediately seek medical help.
Last Update:2024-04-09 21:04:16